The onset of cardiovascular events and risk factors is high among those living with narcolepsy, even among patients who do not have a history of these cardiovascular conditions. As a result, patients’ physicians need to consider cardiovascular risks when considering treatment plans for those living with the sleep disorder.1
These are the conclusions of the CardioVascular Burden Of Narcolepsy Disease (CV-BOND) study that Rami H. Ben-Joseph, Ph.D., head of big data real world evidence at Jazz, recently presented at the American Academy of Neurology (AAN) Annual Meeting 2022.
Existing research has shown that high rates of comorbidities are seen in people living with narcolepsy, a chronic neurological condition that often requires long-term treatment, resulting in a substantial impact on these patients’ lives. Additionally, narcolepsy has been associated with an increased risk of hypertension and cardiovascular disease.2,3
The CV-BOND study set out to measure this excess risk of new-onset cardiovascular events in adults living with narcolepsy. To do so, researchers conducted a retrospective analysis of U.S. Healthcare claims from the IBM® MarketScan® database. Cardiovascular outcomes assessed included any stroke, atrial fibrillation, heart failure, myocardial infarction, among others.
Each analysis was applied to a patient population that did not have an event of interest in the six-month period prior to study entry. Patients were followed from one day after cohort entry until they experienced the outcome of interest for that analysis, or end of study period. Differences in outcome incidences between the narcolepsy (n=12,816) and non-narcolepsy (38,441) cohorts were evaluated using a Cox proportional hazard model adjusted for age, sex, region, insurance type and relevant morbidities and comorbidities.
At baseline, patients living with narcolepsy had more comorbidities compared with those not living with the sleep disorder. This included higher rates of sleep apnea, hypersomnia, mood and anxiety disorders, diabetes and prior cardiovascular disease.1
As expected, unadjusted incidence rates for new-onset cardiovascular events were higher in patients with narcolepsy than those without, including any stroke (4.3 versus 2.2 unadjusted incidence per 1,000 person-years), cardiovascular disease (13.3 versus 8.0) and heart failure (5.7 versus 3.4). The only exception to this was myocardial infarction, as few of these happened across the study.1
Of note, adjusted hazard ratios of the study demonstrated increased risk of new-onset cardiovascular risks in those living with narcolepsy. Differences were observed in events such as stroke (Adjusted HR [95% CI] 1.71), heart failure (1.35), major adverse cardiac events (1.45) and cardiovascular disease (1.30), with the only outlier being atrial fibrillation (0.98).1
In conclusion, the CV-BOND study built upon previous research to prove the onset of cardiovascular events and risk factors is high among people with narcolepsy, even those who do not have a history of each condition. The clinical profile of these patients is dynamic and evolving, which increases their risk of negative cardiovascular outcomes in the future. Because the research established that even patients who are not currently presenting cardiovascular disease are at a higher risk for these events in the future, physicians must keep this correlation in mind when determining the best treatment plan.
To learn more about the cardiovascular comorbidities associated with narcolepsy, healthcare providers can visit narcolepsylink.com.
الإبلاغ عن أثر جانبي
إذا كنت ترغب في الإبلاغ عن أثر جانبي مرتبط بالمنتجات الدوائية لشركة Jazz Pharmaceuticals، يُرجى إرسال بريد إلكتروني إلينا عبر الرابط التالي:
يُرجى تقديم أكبر قدر ممكن من المعلومات المتاحة.
تشمل المعلومات ذات الصلة ما يلي:
بتقديمك لتقريرك وتزويدنا ببيانات الاتصال الخاصة بك، فإنك تُقرّ وتوافق صراحةً على أنه يجوز لقسم السلامة الدوائية المحلي التواصل معك بغرض طلب معلومات إضافية أو توضيحات، إذا اعتُبر ذلك ضروريًا لتقييم التقرير ومتابعته.
يوضح إشعار الخصوصية الخاص بنا المتعلق باليقظة الدوائية والمعلومات الطبية وشكاوى المنتجات كيفية تعامل شركة Jazz Pharmaceuticals مع معالجة المعلومات الشخصية عند التعامل مع تقريرالأثر الجانبي الخاص بك، وهو متاح في مركز الخصوصية لدينا.
Report an Adverse Event
If you want to report a Adverse Event related to Jazz Pharmaceuticals medicinal products, then please send us an e-mail via this link:
Please provide as much available information as possible.
Relevant information includes:
By submitting your report and providing your contact details, you expressly acknowledge and agree that the local drug safety department may contact you for the purpose of requesting additional information or clarifications, should this be deemed necessary for the assessment and follow‑up of the report.
Our Privacy Notice for Pharmacovigilance, Medical Information and Product Complaints outlines how Jazz Pharmaceuticals handles the processing of personal information when dealing with your adverse event report and is available in our Privacy Center.
